HORIZON-PFT (Pivotal Fracture Trial) will study the effect of zoledronic acid, given once per year, on the treatment of osteoporosis in women past menopause. Hip and vertebral fractures are the most devastating consequences of osteoporosis. HORIZON-PFT is designed to determine the benefits of zoledronic acid in fracture reduction at both the hip and spine.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
7,700
Incidence of hip fxs
Incidence of new vertebral fxs
Percent change in hip BMD
New and/or worsening vertebral fxs
All clinical fxs
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Arizona Arthritis Research
Paradise Valley, Arizona, United States
Southern Arizona VA
Tucson, Arizona, United States
University of Arkansas for Medical Science
Little Rock, Arkansas, United States
Osteoporosis Medical Center
Beverly Hills, California, United States
Orthopaedic Hospital
Los Angeles, California, United States
The Foundation for Osteoporosis Research and Education
Oakland, California, United States
University of California Davis- Gen Med Research
Sacramento, California, United States
Osteoporosis Prevention Center
San Diego, California, United States
Radiant Research- San Diego
San Diego, California, United States
...and 50 more locations